Humacyte (HUMAW) to Release Earnings on Thursday

Humacyte (NASDAQ:HUMAW) is projected to release its results before the market opens on Thursday, March 26th. Analysts expect Humacyte to post earnings of ($0.1317) per share and revenue of $1.3490 million for the quarter.

Humacyte Stock Performance

Shares of NASDAQ HUMAW opened at $0.10 on Thursday. Humacyte has a 12-month low of $0.08 and a 12-month high of $1.00. The firm has a 50 day moving average of $0.12 and a 200 day moving average of $0.16.

Humacyte Company Profile

Humacyte, Inc (NASDAQ:HUMAW) is a clinical-stage biotechnology company specializing in the development and manufacture of human acellular vessels (HAVs). These off-the-shelf, bioengineered vascular conduits are designed to serve as living implants for patients requiring vascular access, including those undergoing hemodialysis, as well as for peripheral artery disease and vascular trauma. Humacyte’s proprietary tissue-engineering platform leverages human vascular cells cultured on biodegradable scaffolds, which are subsequently decellularized to produce durable, non-immunogenic vessels that support natural tissue regeneration.

Founded in 2007 and headquartered in Durham, North Carolina, Humacyte has advanced its lead candidate, the HAV, through multiple clinical trials in the United States and Europe.